Charles Allerson

Chief Technology Officer, South San Francisco, California, United States

Professional Overview

Charles Allerson is an accomplished Chief Technology Officer with over 20 years of experience in the pharmaceutical and biotechnology industry. He is a seasoned leader in chemistry, drug development, and technology innovation, with a proven track record of driving transformative solutions and delivering measurable business impact.

Experience Summary

Current Role

As the Chief Technology Officer at Switch Therapeutics, Charles is responsible for overseeing the company's technology strategy, leading the development of innovative drug discovery platforms, and ensuring the seamless integration of cutting-edge technologies across the organization. Under his guidance, Switch Therapeutics has been at the forefront of advancing novel therapeutic approaches, leveraging his extensive expertise in chemistry and drug development.

Career Progression

Charles has held several senior leadership roles throughout his distinguished career, including serving as the SVP of Chemistry at DTx Pharma, a Novartis Company, where he managed a team of over 50 scientists and played a pivotal role in the development of several groundbreaking drug candidates. Prior to that, he served as the Vice President of Chemistry and Drug Development at DTx Pharma, leading the company's chemistry and drug development efforts, and the VP of Chemistry at Stoke Therapeutics, where he spearheaded the development of innovative RNA-based therapeutics.

Earlier in his career, Charles held positions as the Director of Chemistry at Regulus Therapeutics and a Senior Scientist at Isis Pharmaceuticals (now Ionis Pharmaceuticals), where he made significant contributions to the advancement of nucleic acid-based therapies. He also completed a postdoctoral research fellowship at the National Institutes of Health, further solidifying his expertise in the field of chemistry and drug discovery.

Academic Background

Charles holds a Ph.D. in Organic Chemistry from the University of Chicago, where he specialized in the development of novel synthetic methodologies and the total synthesis of natural products. His academic achievements include numerous publications in peer-reviewed journals and presentations at prestigious scientific conferences.

Areas of Expertise

• Expertise in small molecule and nucleic acid-based drug discovery and development

• Deep knowledge of medicinal chemistry, synthetic organic chemistry, and analytical chemistry

• Proven leadership in managing cross-functional teams and driving strategic initiatives

• Proficient in the design, development, and implementation of cutting-edge drug discovery platforms

• Extensive experience in navigating the regulatory landscape and advancing drug candidates through clinical trials

Professional Impact

Under Charles' leadership, Switch Therapeutics has made significant strides in advancing its pipeline of innovative therapeutics, including the successful progression of multiple drug candidates into clinical trials. His technical expertise, coupled with his strategic vision and collaborative approach, has been instrumental in driving the company's growth and positioning it as a leader in the field of targeted drug delivery.

Conclusion

With his extensive experience, technical expertise, and proven track record of success, Charles Allerson is a highly sought-after Chief Technology Officer in the pharmaceutical and biotechnology industry. His commitment to innovation, coupled with his ability to lead cross-functional teams and deliver measurable results, makes him a valuable asset to organizations seeking to push the boundaries of drug discovery and development.